StemCell Institute
TSE:7096
StemCell Institute
TSE:7096
Price:
784
JPY
1.03%
Market Cap:
¥8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
StemCell Institute
TSE:7096
|
JP |
|
F
|
Foschini Group Ltd
JSE:TFG
|
ZA |
|
John Menzies PLC
LSE:MNZS
|
UK |
|
Beat Holdings Ltd
TSE:9399
|
KY |
|
J
|
Jain Irrigation Systems Ltd
BSE:500219
|
IN |
|
S.Ishimitsu & Co Ltd
TSE:2750
|
JP |
Balance Sheet
Balance Sheet Decomposition
StemCell Institute
StemCell Institute
Balance Sheet Decomposition is not available for
StemCell Institute
StemCell Institute
Balance Sheet
StemCell Institute
StemCell Institute
Currency: JPY
| Mar-2018 | Mar-2019 | Mar-2020 | Mar-2021 | Mar-2022 | Mar-2023 | Mar-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
2 107
|
2 465
|
3 025
|
2 743
|
3 511
|
3 324
|
2 846
|
3 201
|
|
| Cash Equivalents |
2 107
|
2 465
|
3 025
|
2 743
|
3 511
|
3 324
|
2 846
|
3 201
|
|
| Total Receivables |
73
|
177
|
278
|
344
|
593
|
1 137
|
1 584
|
1 836
|
|
| Accounts Receivables |
73
|
177
|
278
|
279
|
593
|
1 137
|
1 584
|
1 836
|
|
| Other Receivables |
0
|
0
|
0
|
65
|
0
|
0
|
0
|
0
|
|
| Inventory |
11
|
13
|
16
|
32
|
40
|
39
|
42
|
51
|
|
| Other Current Assets |
17
|
21
|
30
|
30
|
34
|
45
|
43
|
84
|
|
| Total Current Assets |
2 209
|
2 676
|
3 348
|
3 150
|
4 178
|
4 545
|
4 515
|
5 172
|
|
| PP&E Net |
80
|
81
|
106
|
577
|
648
|
648
|
665
|
1 156
|
|
| PP&E Gross |
80
|
81
|
106
|
577
|
648
|
648
|
665
|
1 156
|
|
| Accumulated Depreciation |
234
|
257
|
281
|
307
|
394
|
490
|
575
|
682
|
|
| Intangible Assets |
16
|
6
|
8
|
16
|
25
|
25
|
42
|
132
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
133
|
138
|
138
|
137
|
|
| Long-Term Investments |
0
|
0
|
0
|
105
|
105
|
243
|
513
|
682
|
|
| Other Long-Term Assets |
43
|
50
|
102
|
111
|
127
|
212
|
670
|
221
|
|
| Total Assets |
2 349
N/A
|
2 813
+20%
|
3 565
+27%
|
3 958
+11%
|
5 216
+32%
|
5 812
+11%
|
6 543
+13%
|
7 501
+15%
|
|
| Liabilities | |||||||||
| Accounts Payable |
11
|
17
|
17
|
21
|
30
|
30
|
35
|
25
|
|
| Accrued Liabilities |
29
|
39
|
55
|
58
|
60
|
66
|
71
|
88
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
2
|
67
|
|
| Other Current Liabilities |
1 469
|
1 776
|
2 230
|
2 509
|
2 962
|
3 334
|
3 651
|
4 138
|
|
| Total Current Liabilities |
1 509
|
1 831
|
2 302
|
2 589
|
3 052
|
3 432
|
3 760
|
4 318
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
5
|
7
|
452
|
|
| Other Liabilities |
0
|
0
|
3
|
47
|
60
|
77
|
84
|
103
|
|
| Total Liabilities |
1 509
N/A
|
1 831
+21%
|
2 305
+26%
|
2 636
+14%
|
3 112
+18%
|
3 513
+13%
|
3 850
+10%
|
4 873
+27%
|
|
| Equity | |||||||||
| Common Stock |
375
|
375
|
375
|
375
|
705
|
705
|
705
|
705
|
|
| Retained Earnings |
205
|
348
|
625
|
688
|
809
|
1 007
|
1 318
|
1 448
|
|
| Additional Paid In Capital |
260
|
260
|
260
|
260
|
590
|
590
|
590
|
590
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
3
|
80
|
21
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
94
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
840
N/A
|
982
+17%
|
1 260
+28%
|
1 322
+5%
|
2 104
+59%
|
2 299
+9%
|
2 693
+17%
|
2 628
-2%
|
|
| Total Liabilities & Equity |
2 349
N/A
|
2 813
+20%
|
3 565
+27%
|
3 958
+11%
|
5 216
+32%
|
5 812
+11%
|
6 543
+13%
|
7 501
+15%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
10
|
10
|
10
|
10
|
10
|
10
|
10
|
10
|
|
Switch to:
Switch to:
See Also
Discover More
